Prevention of antibody-mediated kidney transplant rejection

Transplant International

Volumn 25, Issue 6, 2012, Pages 633-645

  Morath, Christian ^a   Opelz, Gerhard ^a   Zeier, Martin ^a   Süsal, Caner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

antibody mediated rejection; desensitization; HLA antibodies; kidney transplantation; sensitization

Indexed keywords

ALLOANTIBODY; ANTIBODY; BORTEZOMIB; DONOR SPECIFIC HLA ANTIBODY; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; CONFERENCE PAPER; DESENSITIZATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GRAFT FAILURE; GRAFT SURVIVAL; HEALTH PROGRAM; HEMODIALYSIS; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; ORGAN DONOR; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ALGORITHMS; BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; DESENSITIZATION, IMMUNOLOGIC; ERYTHROPOIETIN; GRAFT REJECTION; HEMATINICS; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MEDICATION ADHERENCE; TISSUE AND ORGAN PROCUREMENT;

EID: 84861170919     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01490.x     Document Type: Conference Paper

References (71)

1. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
2. Eurotransplant International Foundation Annual Report 2010. Edited by Arie Oosterlee and Axel Rahmel. Central Office. Leiden. The Netherlands.
3. Fuggle SV, Martin S,. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86: 384.
4. Collaborative Transplant Study, University of Heidelberg, Germany, Website. Available at:. Accessed November 21, 2011.
5. Süsal C, Döhler B, Opelz G,. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70: 569.
6. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
7. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
8. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ,. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13: 2027.
9. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD,. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88: 23.
10. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111.
11. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
12. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
13. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
14. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011; 91: 883.
15. Lefaucheur C, Antoine C, Suberbielle C, Glotz D,. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592.
16. Süsal C, Opelz G,. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269.
17. Doxiadis II, Smits JM, Persijn GG, Frei U, Claas FH,. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77: 615.
18. Claas FH, Rahmel A, Doxiadis II,. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447.
19. Montgomery RA,. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010; 10: 449.
20. Morath C, Zeier M, Süsal C,. Desensitization of HLA-incompatible kidney recipients. N Engl J Med 2011; 365: 1644; author reply.
21. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519.
22. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
23. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
24. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
25. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
26. Beimler JH, Morath C, Schmidt J, et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009; 87: 668.
27. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033.
28. Tyan DB, Li VA, Czer L, Trento A, Jordan SC,. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
29. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335.
30. Watanabe J, Scornik JC,. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5: 2786.
31. Montgomery RA, Zachary AA,. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535.
32. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
33. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M,. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
34. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
35. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696.
36. Haas M, Bohmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503.
37. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
38. Gjorstrup P, Berntorp E, Larsson L, Nilsson IM,. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991; 61: 244.
39. Belak M, Borberg H, Jimenez C, Oette K,. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994; 15: 419.
40. Morath C, Becker LE, Leo A, et al. ABO-Incompatible Kidney Transplantation Enabled by Non-Antigen-Specific Immunoadsorption. Transplantation 2012; 93: 827.
41. Goldammer A, Derfler K, Herkner K, Bradwell AR, Horl WH, Haas M,. Influence of plasma immunoglobulin level on antibody synthesis. Blood 2002; 100: 353.
42. Biesenbach P, Schmaldienst S, Smolen JS, Horl WH, Derfler K, Stummvoll GH,. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl 2009; 10: 114.
43. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
44. Steinmetz OM, Lange-Husken F, Turner JE, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842.
45. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
46. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
47. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
48. Wahrmann M, Haidinger M, Kormoczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385.
49. Cascio P, Oliva L, Cerruti F, et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008; 38: 658.
50. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389.
51. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405.
52. Dorling A,. Transplant accommodation-are the lessons learned from xenotransplantation pertinent for clinical allotransplantation? Am J Transplant 2012; 12: 545.
53. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS,. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719.
54. Ratner LE, Rana A, Ratner ER, et al. The altruistic unbalanced paired kidney exchange: proof of concept and survey of potential donor and recipient attitudes. Transplantation 2010; 89: 15.
55. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I,. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145.
56. Stegall MD, Dean PG, Gloor J,. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998.
57. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
58. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010; 89: 178.
59. Nankivell BJ, Alexander SI,. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451.
60. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
61. Opelz G, Döhler B,. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008; 86: 371.
62. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
63. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
64. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90: 645.
65. Süsal C, Morath C,. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011; 77: 177.
66. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
67. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84: 876.
68. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
69. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
70. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
71. Morath C, Schmidt J, Opelz G, Zeier M, Süsal C,. Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? Langenbecks Arch Surg 2011; 396: 467.